Appointment of Medical Supply Company of Ireland
MISSISSAUGA, March 24, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces the appointment of The Medical Supply Company of Ireland (MSC) as a distributor.
Under an agreement between the parties, MSC has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for the Republic of Ireland and Northern Ireland. As distributor, MSC will provide marketing, distribution, and logistical support for Microbix’s QAPs. At present, there are four dozen such QAPs across the PROCEEDx™ and REDx™ Controls tradenames – to support the whole-process accuracy of tests for bacterial and viral diseases by emulating patient samples while being consistent, non-infectious, and stable.
MSC is a privately-owned life sciences distribution company with highly-trained technical sales people providing analytical consumables, diagnostic equipment and other solutions to customers in the fields of life science and clinical diagnostics. MSC is particularly interested in Microbix’s Human Papilloma Virus (HPV) and Mycoplasma genitalium (MGEN) control products, two diseases at the forefront of sexual health testing, as MSC services a number of clinical laboratories performing these tests using equipment from manufacturers that have verified the performance of those Microbix products.
Phil Casselli, SVP of Sales and Business Development of Microbix stated, “We’re pleased to have MSC become a distribution partner for our QAPs product lines. They are the major provider of laboratory supply materials, diagnostic controls and technical support for the Republic of Ireland and Northern Ireland, with well-trained marketing and sales staff and a team of field service professionals. Microbix believes MSC will provide QAPs customers with excellent user training and after sales support for our growing PROCEEDx™ and REDx™ Controls product lines.”
Lisa Tang, Life Sciences Sales Manager for MSC also commented, “We’re excited to be providing Microbix’s innovative QAPs to our diagnostics customers. These QAPs will complement our portfolio of controls and supplies for sexually-transmitted, respiratory, gastrointestinal, and hospital-acquired pathogens. Training of MSC staff about QAPs is underway and we’re now stocking these products for our customers.”
About Microbix Biosystems
Microbix develops proprietary biological and technology solutions for human health and well-being, with sales now exceeding $1 million per month on average and approximately 80 skilled employees. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure quality control of clinical diagnostic tests. Microbix antigens and QAPs are sold to many customers worldwide, at present primarily to multinational diagnostics companies and laboratory accreditation organizations.
Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots.
Microbix is a publicly-traded company, listed on the Toronto Stock Exchange and headquartered in Mississauga, Ontario, Canada. Distribution inquiries should be directed to firstname.lastname@example.org.
About Medical Supply Company of Ireland
Medical Supply Company was established in 1971 and is an Irish owned Company. MSC is ISO 9001 accredited and distributes laboratory products to research, diagnostic, and industrial laboratories. MSC is one of the largest laboratory supply companies in Ireland and has nine sales representatives, all educated to PhD, MSc, or degree level, accompanied by eight service engineers trained to support the equipment it supplies.
This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of the distribution agreement or MSC, the referenced product lines, Microbix’s business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.
Please visit www.microbix.com or www.sedar.com for recent Microbix news and filings.
For further information, please contact Microbix at:
|Cameron Groome, CEO
|Jim Currie, CFO
|Deborah Honig, Investor Relations
Adelaide Capital Markets
(647) 203-8793 email@example.com
Copyright © 2020 Microbix Biosystems Inc.